Comparing the current results to its competitors, 180 Life Sciences reported Revenue increase in the 2 quarter 2026 by 0 % year on year. The revenue growth was below 180 Life Sciences's competitors' average revenue growth of 5.33 %, achieved in the same quarter.
180 Life Sciences Corp, slower than the average decrease reported by the company's competitors of -73.27 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -73.27 %
180 Life Sciences's Comment on Competition and Industry Peers
The Company operates in competitive markets that include traditional financial services, financial technology platforms, and digital asset infrastructure providers. In asset origination and financing, its competitors consist of traditional financial institutions, specialty finance companies, and financial technology platforms that originate or finance consumer credit and other income-generating financial assets. Many of these competitors possess greater financial resources, longer operating histories, and established customer relationships. In the emerging market for tokenized real-world assets (RWAs), the Company competes with digital asset infrastructure providers and financial technology firms developing tokenization platforms and digital securities infrastructure. These competitors include regulated digital asset platforms, blockchain infrastructure providers, and financial institutions exploring tokenized financial products. Additionally, certain large financial institutions and asset managers are exploring blockchain-based financial infrastructure initiatives.
Puma Biotechnology Inc operates as a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of cancer. Their business model revolves around identifying promising preclinical and clinical drug candidates, conducting rigorous research and development, and seeking regulatory approval for their products. Puma Biotechnology Inc strives to effectively market and distribute their approved therapeutics to provide patients with potentially life-saving treatment options.
Vertex Pharmaceuticals Incs business model centers on the research and development of innovative therapies, primarily targeting cystic fibrosis and other serious diseases. They emphasize collaboration with organizations, strategic partnerships, and robust investment in R&D to deliver transformative treatments to patients and enhance their quality of life.
Bausch Health Companies Inc operates through three segments: Bausch + Lomb/International, Salix, and Ortho Dermatologics. The company focuses on developing, manufacturing, and marketing a wide range of pharmaceutical products, medical devices, and over-the-counter products primarily in the areas of eye health, gastroenterology, and dermatology. Bausch Health aims to provide innovative and quality healthcare solutions to improve patients' lives globally.
Jazz Pharmaceuticals Plc is a biopharmaceutical company focused on developing and commercializing innovative therapies for a range of medical conditions. Their business model revolves around conducting extensive research and development to identify novel molecules and compounds that can address unmet medical needs. By leveraging strategic partnerships, acquisitions, and licensing agreements, they aim to bring these therapies to market and provide valuable treatment options to patients worldwide.
Royalty Pharma Plc operates as a pharmaceutical investment company, focusing on acquiring and managing royalty interests in approved drugs. Their business model primarily revolves around purchasing existing royalty streams in exchange for upfront payments, allowing them to generate ongoing cash flows from the sales of these drugs. They aim to provide liquidity to stakeholders, such as biotech and pharmaceutical companies, by offering a financial alternative to traditional financing options.
Sources:
180 Life Sciences Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on 180 Life Sciences Corp versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
